A naturally occurring compound produced by gut bacteria is attracting fresh attention from multiple sclerosis researchers after a clinical trial found that propionic acid supplementation was associated with a meaningful reduction in a blood marker linked to nerve damage.

The findings come from the phase 2b Multiple sclerosis And DisAbility Improvement, or MADAI, trial, which investigated whether propionic acid could provide additional benefits when used alongside existing multiple sclerosis treatment. The results have raised interest in the possibility that the compound could eventually become part of a broader strategy aimed not only at controlling inflammation but also at protecting the nervous system.

However, the findings should be viewed as an encouraging research development rather than a new treatment recommendation. The study was relatively small and lasted only 90 days, and the main improvement was seen in a biomarker rather than a confirmed reduction in long-term disability. Larger and longer clinical trials will be needed before doctors can determine whether propionic acid produces meaningful benefits for people living with MS.

Multiple sclerosis is a complex neurological disease in which the immune system mistakenly attacks parts of the central nervous system. The resulting inflammation can damage myelin, the protective covering around nerve fibres, and in some cases can also contribute to injury of the nerve fibres themselves.

That damage can eventually affect how efficiently signals travel through the nervous system. Depending on the areas involved, people with MS may experience symptoms such as weakness, sensory changes, balance difficulties, visual problems, fatigue or cognitive challenges.

Current MS treatments primarily focus on controlling abnormal immune activity and reducing disease activity. While these therapies have transformed the management of MS, researchers continue to look for additional approaches that could help protect nerve cells and limit neurological damage.

This is where propionic acid has attracted scientific interest.

Propionic acid is a short-chain fatty acid produced naturally when certain gut bacteria break down dietary fibre. It is one of several compounds produced through the interaction between the foods people consume and microorganisms living in the digestive tract.

Researchers have become increasingly interested in the relationship between the gut microbiome and neurological health. Earlier studies have suggested that people with multiple sclerosis may have lower levels of propionic acid than individuals without the disease. Laboratory and early clinical research has also indicated that propionic acid may influence immune activity and processes relevant to nervous-system health.

The latest trial provides a more controlled test of that idea.

The MADAI study involved 101 adults with clinically stable multiple sclerosis. Participants were randomly assigned in a two-to-one ratio to receive either propionic acid or a matching placebo. Those receiving the active treatment took 500 milligrams twice a day for 90 days.

The trial was randomised, double-blinded and placebo-controlled, meaning neither participants nor researchers knew which individuals were receiving the active compound during the relevant stages of the study. Such a design is important because it reduces the possibility that expectations or other factors will influence the results.

Researchers focused primarily on serum neurofilament light chain, commonly known as sNfL.

This protein fragment has become an important research marker in neurological medicine. When nerve fibres are injured, neurofilament proteins can be released and detected in blood. Higher or changing levels of neurofilament light chain can therefore provide researchers with information about neuroaxonal injury.

It is important to understand what this marker can and cannot tell us.

A reduction in sNfL is encouraging because it may indicate less ongoing nerve-fibre injury. But a change in a biomarker does not automatically mean that a patient will experience fewer symptoms, regain lost abilities or avoid disability in the long term.

That distinction is especially important in interpreting the new propionic acid findings.

In the trial, participants receiving propionic acid experienced a 17.9% reduction in serum neurofilament light chain. Average levels fell from 9.77 picograms per millilitre to 8.02 picograms per millilitre. The placebo group did not show a comparable significant change. The researchers reported a statistically significant difference between the groups after adjustment for relevant factors.

The signal was also observed among participants who were already receiving moderate-to-high-efficacy disease-modifying treatments.

This is potentially important because the researchers were not testing propionic acid as a replacement for standard MS therapy. Instead, the compound was investigated as an add-on approach.

That distinction could shape future research.

Modern MS care already includes treatments designed to suppress or modify harmful immune activity. A future therapy that could complement those medicines by helping address nerve injury would potentially fill a different part of the treatment gap.

The study also produced an encouraging safety signal. No serious adverse events related to the study medication were reported, and the investigators described propionic acid as well tolerated during the trial. There was also a trend toward improvement in motor fatigue among participants receiving the compound.

Still, the fatigue finding needs to be interpreted carefully.

A trend is not the same as a statistically established clinical benefit. The study was primarily designed around the biomarker outcome, and a larger trial would be better positioned to determine whether propionic acid actually improves symptoms, physical function, cognition, quality of life or disability progression.

That is why researchers are calling for further investigation rather than suggesting that the compound is ready for routine MS treatment.

The new findings build on earlier work examining the role of propionic acid in MS. Previous research has suggested that the compound may influence immune regulation, including pathways involving different types of T cells. Laboratory research has also explored whether propionic acid could support neuronal processes.

Together, these findings have helped create a scientific theory around the gut-immune-brain connection.

The idea is not that the gut alone causes multiple sclerosis or that changing gut bacteria can cure the condition. Rather, researchers are investigating whether metabolites produced by gut microorganisms can influence immune behaviour and neurological processes in ways that may affect disease activity.

That field remains relatively young.

The microbiome contains enormous numbers of microorganisms capable of producing a wide range of biologically active substances. Understanding which compounds are beneficial, which may be harmful and how those substances interact with individual patients is a complicated scientific challenge.

Propionic acid is therefore one piece of a much larger puzzle.

The latest trial is valuable because it moves the discussion beyond laboratory experiments and early observational findings into a controlled clinical setting. At the same time, its limitations show why the research should not be overinterpreted.

The trial involved just 101 participants and was conducted at a single centre. Treatment lasted only three months. Multiple sclerosis, however, is a long-term condition, and meaningful changes in disability or disease progression may require much longer observation.

Researchers also need to determine whether the reduction in sNfL remains stable with prolonged supplementation and whether it translates into measurable improvements that patients can actually feel.

A larger phase 3 study could answer some of these questions.

Future research may also examine whether particular groups of people with MS respond better than others. Researchers could investigate differences based on disease type, existing treatments, disease activity, microbiome characteristics or other biological factors.

Such information could eventually help determine whether propionic acid has a specific role as an add-on therapy.

For now, people living with MS should not interpret these results as evidence that they should begin taking propionic acid supplements independently.

The study used a specific pharmaceutical-style dose under clinical research conditions, and commercially available products may differ considerably in formulation, dose and quality. There is also no evidence from this trial that propionic acid should replace approved MS medicines.

Any decision involving supplements or changes to MS treatment should be discussed with a qualified healthcare professional.

The most important message from the research is therefore one of cautious optimism.

The results suggest that propionic acid may influence a biological process associated with nerve injury in multiple sclerosis. That is potentially significant because protecting nerve fibres remains an important unmet need in MS research.

For years, much of the focus in MS treatment has centred on controlling inflammation and preventing new disease activity. Researchers are increasingly interested in the next challenge: how to protect the nervous system itself and preserve neurological function over the long term.

Propionic acid could become part of that conversation if future trials confirm the early findings.

The next stage will be crucial. Larger studies with longer follow-up will need to determine whether the biomarker improvement translates into tangible clinical benefits and whether the treatment remains safe and useful over time.

Until then, the new evidence should be regarded as a promising step rather than a breakthrough treatment.

For multiple sclerosis research, however, even that step matters.

A simple compound produced naturally by gut bacteria has now shown a measurable effect on a marker of nerve injury in a controlled clinical trial. The finding strengthens the case for investigating the connection between the gut, immune system and nervous system in greater depth.

If future research confirms that propionic acid can protect nerve tissue and improve meaningful outcomes for people with MS, it could eventually add a new dimension to treatment.

For now, the science has opened an intriguing door.

The next question is whether larger trials can show that what looks promising in a blood test can ultimately make a real difference in the lives of people living with multiple sclerosis.